Table 2 Summary results of network meta-analysis: posterior ORs or MDs with their 95% credible intervals of all treatment strategies and SUCRA values
| Â | Clinical response versus placebo | |
| Â | Median OR (95% CrI) | SUCRA |
Ulnar-I | 128.30 (9.76 to 2299.00) | 98% |
DI | 7.00 (0.53 to 118.80) | 46% |
PI | 8.85 (3.00 to 33.15) | 54% |
| Â | Change in symptom severity scale versus placebo | |
| Â | Median MD (95% CrI) | SUCRA |
Ulnar-I | −1.16 (−1.95 to −0.38) | 95% |
Ulnar-O | −0.78 (−1.43 to −0.16) | 64% |
PI | −0.58 (−0.95 to −0.22) | 40% |
| Â | Change in functional status scale versus placebo | |
| Â | Median MD (95% CrI) | SUCRA |
Ulnar-I | −0.74 (−2.00 to 0.52) | 78% |
Ulnar-O | −0.63 (−1.67 to 0.43) | 67% |
PI | −0.46 (−1.11 to 0.21) | 48% |